NGM's eye drug fails in a Phase 2 clinical trial
marketwatch.com
news
2022-10-17 12:48:11

Shares of NGM Biopharmaceuticals Inc. NGM, -5.94% tumbled 67.4% in premarket trading on Monday after the company said its experimental treatment for an advanced form of macular degeneration did not meet the primary endpoint in a Phase 2 clinical trial. NGM said it plans to share additional information from the study at the Retina Society's annual meeting next month. The company's stock is down 34.8% this year, while the broader S&P 500 SPX, -2.37% has declined 24.8%.
